NCT03459521View on ClinicalTrials.gov

Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease.

NACompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

August 1, 2021

Study Completion Date

August 1, 2021

Conditions
Liver Disease ChronicHepatitis B Virus
Interventions
BIOLOGICAL

Fendrix or HBVAXPRO 40

To administer hepatitis B virus vaccines in patients with chronic liver disease that have not been previously vaccinated.

Trial Locations (1)

08221

Hospital Universitari Mutua Terrassa, Terrassa

Sponsors
All Listed Sponsors
lead

Corporacion Parc Tauli

OTHER